Cited by 622

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Characterization of tumor necrosis factor-deficient mice

Marino, Michael W., Dunn, Ashley, Grail, Dianne, Inglese, Melissa, Noguchi, Yuji, Richards, Elizabeth, Jungbluth, Achim, Wada, Hisashi, Moore, Malcolm, Williamson, Barbara, Basu, Sunanda, Old, Lloyd J.·1997·Proceedings of the National Academy of Sciences

Abstract

Although tumor necrosis factor (TNF) initially came to prominence because of its anti-tumor activity, most attention is now focused on its proinflammatory actions. TNF appears to play a critical role in both early and late events involved in inflammation, from localizing the noxious agent and amplifying the cellular and mediator responses at the local site and systemically, to editing (e.g., apoptosis) injured cells or effete immune cells and repairing inflammatory damage. We have generated mice deficient in TNF (TNF −/− mice) and have begun to examine the multiple functions attributed to TNF. TNF −/− mice develop normally and have no gross structural or morphological abnormalities. As predicted, they are highly susceptible to challenge with an infectious agent ( Candida albicans ), are resistant to the lethality of minute doses of lipopolysaccharide (LPS) following D-galactosamine treatment, have a deficiency in granuloma development, and do not form germinal centers after immunization. Phagocytic activity of macrophages appears relatively normal, as do T cell functions, as measured by proliferation, cytokine release, and cytotoxicity. B cell response to thymus-independent antigens is normal, but the Ig response to thymus-dependent antigen is reduced. Surprisingly, cytokine production induced by LPS appears essentially intact, with the exception of reduced colony-stimulating factor activity. Other unexpected findings coming from our initial analysis are as follows. ( i ) TNF has low toxicity in TNF −/− mice. ( ii ) TNF −/− mice show an anomalous late response to heat-killed Corynebacterium parvum . In contrast to the prompt response (granuloma formation, hepatosplenomegaly) and subsequent resolution phase in C. parvum -injected TNF +/+ mice, similarly treated TNF −/− mice show little or no initial response, but then develop a vigorous, disorganized inflammatory response leading to death. These results suggest that TNF has an essential homeostatic role in limiting the extent and duration of an inflammatory process—i.e., an anti-inflammatory function. ( iii ) In contrast to the expectation that TNF +/+ mice and TNF +/− mice would have identical phenotypes, TNF +/− mice showed increased susceptibility to high-dose LPS lethality, increased susceptibility to Candida challenge, and delayed resolution of the C. parvum -induced inflammatory process, indicating a strong gene dose requirement for different actions of TNF.

Overview

Integrity signals

Registry

Crossref · 10.1073/pnas.94.15.8093

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 38

  1. , ed B Beutler (Raven, New York Tumor Necrosis Factors: The Molecules and Their Emerging Role in Medicine, 1992).
  2. , eds B B Aggarwal, J Vilček (Dekker, New York Tumor Necrosis Factors: Structure, Function, and Mechanism of Action, 1992).
  3. 10.1126/science.8171316 · DOI
  4. 10.1126/science.8171323 · DOI
  5. 10.1016/0092-8674(93)90134-C · DOI · Paper page
  6. 10.1038/364798a0 · DOI
  7. 10.1038/372560a0 · DOI
  8. 10.1126/science.8171322 · DOI
  9. T A Banks, B T Rouse, M K Kerley, P J Blair, V L Godfrey, N A Kuklin, D M Bouley, J Thomas, S Kanangat, M L Mucenski J Immunol 155, 1685–1693 (1995). · DOI
  10. 10.1084/jem.183.5.2367 · DOI
  11. 10.1084/jem.184.4.1397 · DOI
  12. F Amiot, Y Bellkaid, M Lebastard, P Ave, F Dautry, G Milon Eur Cytokine Network 7, 733–739 (1996).
  13. 10.1084/jem.184.1.259 · DOI
  14. 10.1126/science.271.5253.1289 · DOI
  15. B Ryffel, F Di Padova, M H Schreier, M Le Hir, H P Eugster, V F Quesniaux J Immunol 158, 2126–2133 (1997). · DOI
  16. 10.1016/0092-8674(91)90011-M · DOI
  17. 10.1242/dev.113.4.1325 · DOI
  18. A Bradley Teratocarcinomas and Embryonic Stem Cells: A Practical Approach, ed E J Robertson (IRL, Oxford), pp. 152–178 (1987).
  19. 10.1016/0022-1759(86)90322-4 · DOI
  20. 10.1016/S0076-6879(85)16044-1 · DOI
  21. 10.3109/08977199409001056 · DOI
  22. 10.1016/0022-1759(94)00247-T · DOI
  23. E J Coligan, A M Kruisbeek, D H Margulies, E M Schevach, W Strober Current Protocols in Immunology (Wiley, New York) 3, 14.0.3–14.9.3 (1994).
  24. H P Redmond, J Shou, H J Gallagher, C J Kelly, J M Daly J Immunol 150, 3427–3433 (1993). · DOI
  25. G Biozzi, B Benacerraf, B N Halpern Br J Pathol 34, 441–457 (1953).
  26. B S Kelly, J G Levy, L Sikora Immunology 37, 45–52 (1979).
  27. 10.1002/eji.1830220412 · DOI
  28. 10.1016/S0021-9258(18)71615-3 · DOI
  29. S Steinshamn, M H Bemelmans, L J van Tits, K Bergh, W A Buurman, A Waage J Immunol 157, 2155–2159 (1996). · DOI
  30. 10.1016/1074-7613(95)90001-2 · DOI
  31. 10.1056/NEJM199606273342603 · DOI
  32. 10.1084/jem.175.6.1759 · DOI
  33. 10.1016/0092-8674(89)90676-4 · DOI
  34. 10.1038/356604a0 · DOI
  35. 10.1038/nm0796-788 · DOI
  36. L Q Vieira, M Goldschmidt, M Nashleanas, K Pfeffer, T Mak, P Scott J Immunol 157, 827–835 (1996). · DOI
  37. S Kondo, B Wang, H Fujisawa, G M Shivji, B Echtenacher, T W Mak, D N Sauder J Immunol 155, 3801–3805 (1995). · DOI
  38. T Zhou, C K Edwards, P Yang, Z Wang, H Bluethmann, J D Mountz J Immunol 156, 2661–2265 (1996). · DOI

Cited by

Sorted by citations

See all 622

Metadata

Authors
Marino, M. W., Dunn, A., Grail, D., Inglese, M., Noguchi, Y., Richards, E., Jungbluth, A., Wada, H., Moore, M., Williamson, B., Basu, S., & Old, L. J.
Affiliations
Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan–Kettering Cancer Center, 1275 York Avenue, New York, NY 10021; Ludwig Institute for Cancer Research, Melbourne Branch, P.O. Box Royal Melbourne Hospital, Melbourne, Australia, 3050; and Department of Experimental Hematology, Memorial Sloan–Kettering Cancer Center, 1275 York Avenue, New York, NY 10021
Venue
Proceedings of the National Academy of Sciences
Published
1997-07-22
Volume
94
Issue
15
Pages
8093-8098
ISSN
  • 0027-8424
  • 1091-6490
Cited by
622
References
2
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review